Abstract
This article highlights preclinical and clinical studies in the field of wasting disorders that were presented at the 7th Cachexia Conference held in Kobe, Japan, in December 2013. This year, the main topics were the development of new methods and new biomarkers in the field of cachexia and wasting disorders with particular focus on inflammatory pathways, growth differentiation factor-15, myostatin, the ubiquitin proteasome-dependent pathway, valosin and the regulation of ubiquitin-specific protease 19 that is involved in the differentiation of myogenin and myosin heavy chain. This article presents highlights from the development of drugs that have shown potential in the treatment of wasting disorders, particularly the ghrelin receptor agonist anamorelin, the myostatin antagonist REGN1033, the selective androgen receptor modulators enobosarm and TEI-E0001, and the anabolic catabolic transforming agent espindolol. In addition, novel data on the prevalence and detection methods of muscle wasting/sarcopenia are presented, including the D3-creatine dilution method and several new biomarkers.
| Original language | English |
|---|---|
| Pages (from-to) | 27-34 |
| Number of pages | 8 |
| Journal | Journal of Cachexia, Sarcopenia and Muscle |
| Volume | 5 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Cachexia
- Muscle wasting
- Sarcopenia
- Therapy
ASJC Scopus subject areas
- Orthopedics and Sports Medicine
- Physiology (medical)
Cite this
Highlights from the 7th Cachexia Conference : Muscle wasting pathophysiological detection and novel treatment strategies. / Ebner, Nicole; Steinbeck, Lisa; Doehner, Wolfram; Anker, Stefan D.; von Haehling, Stephan.
In: Journal of Cachexia, Sarcopenia and Muscle, Vol. 5, No. 1, 2014, p. 27-34.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Highlights from the 7th Cachexia Conference
T2 - Muscle wasting pathophysiological detection and novel treatment strategies
AU - Ebner, Nicole
AU - Steinbeck, Lisa
AU - Doehner, Wolfram
AU - Anker, Stefan D.
AU - von Haehling, Stephan
PY - 2014
Y1 - 2014
N2 - This article highlights preclinical and clinical studies in the field of wasting disorders that were presented at the 7th Cachexia Conference held in Kobe, Japan, in December 2013. This year, the main topics were the development of new methods and new biomarkers in the field of cachexia and wasting disorders with particular focus on inflammatory pathways, growth differentiation factor-15, myostatin, the ubiquitin proteasome-dependent pathway, valosin and the regulation of ubiquitin-specific protease 19 that is involved in the differentiation of myogenin and myosin heavy chain. This article presents highlights from the development of drugs that have shown potential in the treatment of wasting disorders, particularly the ghrelin receptor agonist anamorelin, the myostatin antagonist REGN1033, the selective androgen receptor modulators enobosarm and TEI-E0001, and the anabolic catabolic transforming agent espindolol. In addition, novel data on the prevalence and detection methods of muscle wasting/sarcopenia are presented, including the D3-creatine dilution method and several new biomarkers.
AB - This article highlights preclinical and clinical studies in the field of wasting disorders that were presented at the 7th Cachexia Conference held in Kobe, Japan, in December 2013. This year, the main topics were the development of new methods and new biomarkers in the field of cachexia and wasting disorders with particular focus on inflammatory pathways, growth differentiation factor-15, myostatin, the ubiquitin proteasome-dependent pathway, valosin and the regulation of ubiquitin-specific protease 19 that is involved in the differentiation of myogenin and myosin heavy chain. This article presents highlights from the development of drugs that have shown potential in the treatment of wasting disorders, particularly the ghrelin receptor agonist anamorelin, the myostatin antagonist REGN1033, the selective androgen receptor modulators enobosarm and TEI-E0001, and the anabolic catabolic transforming agent espindolol. In addition, novel data on the prevalence and detection methods of muscle wasting/sarcopenia are presented, including the D3-creatine dilution method and several new biomarkers.
KW - Cachexia
KW - Muscle wasting
KW - Sarcopenia
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=84896397419&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896397419&partnerID=8YFLogxK
U2 - 10.1007/s13539-014-0136-z
DO - 10.1007/s13539-014-0136-z
M3 - Article
AN - SCOPUS:84896397419
VL - 5
SP - 27
EP - 34
JO - Journal of Cachexia, Sarcopenia and Muscle
JF - Journal of Cachexia, Sarcopenia and Muscle
SN - 2190-5991
IS - 1
ER -